Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Oric Pharmaceuticals has a “Moderate Buy” consensus from 16 brokerages: 13 rate it a buy, two recommend holding, and one rates it a sell. The average 12-month price target is $19.27, compared with the stock’s $13.50 opening price.
• Institutional investors hold approximately 95.05% of ORIC shares, with several hedge funds recently increasing their positions or initiating new stakes.
• Oric reported a quarterly loss of $0.38 per share, missing analysts’ $0.36 loss estimate; analysts expect a full-year loss of approximately $1.51 per share.

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the sixteen brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and thirteen have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $19.2727.

Several research firms have recently issued reports on ORIC. Wall Street Zen raised Oric Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday, July 25th. Cantor Fitzgerald restated an "overweight" rating on shares of Oric Pharmaceuticals in a research note on Friday, May 22nd. Weiss Ratings restated a "sell (d-)" rating on shares of Oric Pharmaceuticals in a research note on Friday, July 17th. Citigroup decreased their target price on shares of Oric Pharmaceuticals from $17.00 to $16.00 and set a "buy" rating for the company in a report on Tuesday, May 5th. Finally, Benchmark reiterated a "buy" rating on shares of Oric Pharmaceuticals in a research note on Monday, June 8th.

Hedge Funds Weigh In On Oric Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Defilade Capital Management L.P. purchased a new stake in Oric Pharmaceuticals during the first quarter valued at $10,680,000. Siren L.L.C. lifted its holdings in Oric Pharmaceuticals by 197.6% in the first quarter. Siren L.L.C. now owns 2,998,192 shares of the company's stock valued at $37,987,000 after acquiring an additional 1,990,617 shares during the period. Dimensional Fund Advisors LP boosted its position in Oric Pharmaceuticals by 19.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,471,290 shares of the company's stock worth $18,637,000 after purchasing an additional 244,060 shares during the last quarter. UBS Group AG boosted its position in Oric Pharmaceuticals by 116.6% in the fourth quarter. UBS Group AG now owns 734,858 shares of the company's stock worth $6,011,000 after purchasing an additional 395,622 shares during the last quarter. Finally, Candriam S.C.A. bought a new stake in shares of Oric Pharmaceuticals during the 1st quarter valued at about $7,274,000. 95.05% of the stock is currently owned by hedge funds and other institutional investors.

Oric Pharmaceuticals Price Performance

ORIC stock opened at $13.50 on Monday. Oric Pharmaceuticals has a twelve month low of $7.23 and a twelve month high of $14.93. The firm has a market cap of $1.40 billion, a PE ratio of -10.00 and a beta of 1.02. The business has a 50 day moving average of $10.15 and a 200 day moving average of $10.45.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last released its earnings results on Monday, August 3rd. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.02). On average, research analysts expect that Oric Pharmaceuticals will post -1.51 earnings per share for the current fiscal year.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company's pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source